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Protein stabilityThe human amino acid transporter SLC1A5 (ASCT2) contains two N-glycosylation sites (N163 andN212) located
in the large extracellular loop. In the homology structural model of ASCT2 these Asn residues are extracellularly
exposed. Mutants of the two Asn exhibited altered electrophoretic mobility. N163Q and N212Q displayed
multiple bands with apparent molecular masses from 80 kDa to 50 kDa. N163/212Q displayed a single band of
50 kDa corresponding to the unglycosylated protein. The presence in membrane of WT and mutants was
evaluated by protein biotinylation assay followed by immunoblotting. The double mutation signiﬁcantly
impaired the presence of the protein in membrane, without impairment in protein synthesis. [3H]glutamine
transport wasmeasured in cells transiently transfectedwith theWT ormutants. N163/212Q exhibited a strongly
reduced transport activity correlating with reduced surface expression. The same proteins extracted from
cells and reconstituted in liposomes showed comparable transport activities demonstrating that the intrinsic
transport function of the mutants was not affected. The rate of endocytosis of ASCT2 was assayed by a reversible
biotinylation strategy. N212Q and N163/212Q showed strongly increased rates of endocytosis respect to WT.
ASCT2 stability was determined using cycloheximide. N163Q or N163/212Q showed a slightly or signiﬁcantly
lower stability with respect to WT. To assess trafﬁcking to themembrane, a brefeldin-based assay, which caused
retention of proteins in ER, was performed. One hour after brefeldin removal WT protein was localized
to the plasma membrane while the double mutant was localized in the cytosol. The results demonstrate that
N-glycosylation is critical for trafﬁcking.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Amino acid ﬂux through biological membranes and distribution to
tissues are both ﬁnely controlled by numerous transporters belonging
to different solute carrier (SLC) families. Many of these amino acid
transporters are characterized functionally [1–5] but much is still
unknown concerning their structure/function relationships, protein–
protein interactions and trafﬁcking. Among these transporters,
SLC1A5, known as ASCT2, is one of the most attractive to study due to
its involvement in cell signaling and relevance to human pathology.
ASCT2 was proposed to be a sodium dependent antiporter acceptingl ether;BFA,brefeldin-A;DMEM,
; TX-100, TritonX-100;NP-40,
aminobicyclo-(2,2,1)-heptane-
ercaptoethanesulfonic acid
a, Ecologia e Scienze della Terra)
ta di Rende (CS) Italy. Tel.:+39alanine, serine and cysteine as themajor substrates and also glutamine,
alanine, serine, asparagine, threonine, valine and methionine [6,7].
More recent studies performed in proteoliposomes on the rat or
human proteins revealed that ASCT2 is functionally asymmetrical
since the substrate alanine, valine andmethionine can be only inwardly
transported [8,9]. The ability of ASCT2 to transport glutamine, along
with its ubiquitous tissue expression, suggests that this transporter is
a key player in glutamine homeostasis [10,11]. The potentially impor-
tant role of ASCT2 in human cancer emerged from the ﬁnding that it is
over-expressed in several malignancies together with SLC7A5, also
known as LAT1 [1,12,13]. Over-expression of ASCT2 and LAT1 increases
glutamine uptake allowing cancer cells to produce metabolic energy
from glutamine by a modiﬁed biochemical pathway, typical of cancer
cells, involving glutaminase and some enzymes of the citric acid cycle
[14,15]. ASCT2 has been proposed, in association with LAT1, to be a
plasma membrane component of the mTOR signaling pathway [16,
17]. Therefore, ASCT2 represents a potential pharmacological target in
cancer as well as in pathologies linked to derangements of the mTOR
pathway, such as obesity, type 2 diabetes and neurodegeneration [18].
Over the years, several studies have attempted to identify potent and
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mental strategies [19–21]. However, the main challenge in performing
large scale screening of pharmacological compounds that interact with
ASCT2 is the lack of three-dimensional structure of the transporter.
A crystallographically derived structure of plasma membrane trans-
porters of high eukaryotes is not available, with the exception GLUT1,
which was solved using an inactive form of the protein [22]. Therefore,
data on structure/function relationships for ASCT2 are derived from
homology structural models built using, as template, the glutamate
transporter Gltph from Pyrococcus horikoshii, which possesses enough
similarity to human and rat ASCT2 [23]. From these studies it was
deduced that the rat orthologue, consisting of 16 cysteine (Cys) residues
in its primary structure, harbors the typical metal binding motif, CXXC,
which shows high reactivity towards mercury compounds [24]. The
human orthologue contains only 8 Cys residues and lacks of the CXXC
motif. Even though the overall sequence identity between the rat and
human orthologues is more than 79%, local alignment shows a stretch
of 31 amino acids (aa 200–229), where identity is lower than 14%, sug-
gesting that the human and rat orthologues have different properties
and, hence, the rat protein cannot be used as a model for the human
transporter. The presence of several Cys residues, however, does allow
the human orthologue to interact with SH reagents and this completely
abolishes transport activity. These data indicate that the Cys residues
are important for transport and are accessible to SH reagents [25].
There is considerably less information on the regulation of transport
activity and cell expression of ASCT2 compared to structural features
[1]. Very recently it was shown that transport reaction is modulated
by membrane potential and that the sodium coupled glutamine/
amino acid antiport is electrogenic. Moreover, internal sodium also
regulates transport by allosteric effects. Furthermore, it has been
demonstrated that ASCT2 interacts with the scaffold protein PDZK1
[25] suggesting that protein–protein interactions may be involved in
regulation of the transporter. Some information is available on ASCT2
promoter and regulation via a Raf-MEK-ERK kinase cascade [26].
A completely unexplored aspect of regulation of ASCT2 and most
amino acid transporters is the trafﬁcking to plasma membrane. N-
glycosylation has been linked to trafﬁcking of transporters [27–29]
and represents the most frequent post translational modiﬁcation of
human proteins since more than 50% of proteins are glycosylated [30,
31].We hypothesized that glycosylation could play a role in the trafﬁck-
ing of ASCT2 in mammalian cells and role of glycosyl moieties of the
protein in the process of delivery to plasma membrane was assessed.
Two putative glycosylation sites were predicted by bioinformatics and
were subject to site-directed mutagenesis. The effects on function and
targeting of both WT and mutant isoforms of ASCT2 are reported here
and represent, to our knowledge, the ﬁrst evidence on the role of
glycosyl moiety in trafﬁcking for a human amino acid transporter.2. Materials and methods
2.1. Materials
Human embryonic kidney HEK293 cells were obtained from the
American Type Culture Collection (ATCC). Tissue culture media, fetal
bovine serum, Alexa Fluor 594 anti rabbit and transfection reagent
Lipofectamine were obtained from Life Technologies. PNGase F, restric-
tion endonucleases and other cloning reagents fromNEB (New England
Biolabs); sulfo-NHS-SS-biotin from Thermo Scientiﬁc; ECL plus, Hybond
ECL membranes from GE Healthcare; L-[3H] glutamine from Perkin
Elmer; the anti rabbit IgG HRP conjugate from Cell Signaling; the
QIAEX II Gel Extraction Kit fromQiagen; the Polyjet transfection reagent
was from SignaGen Laboratories; the protease inhibitor mix from
Roche; the rabbit anti-ASCT2 from Millipore, the plasmid p3XFLAG-
CMV-7.1, C12E8, Amberlite XAD-4, egg yolk phospholipids (3-sn-
phosphatidylcoline from egg yolk), Sephadex G-75, L-glutamine,cycloheximide, rabbit anti-FLAG, MESNA, streptavidin beads and all
the other reagents were from Sigma-Aldrich.
2.2. Site-directed mutagenesis
The cDNA of ASCT2was subcloned into p3XFLAG-CMV-7. p3XFLAG-
CMV-7.1 is a 4717bp expression vector used to establish transient
expression of N-terminal FLAG fusion protein in mammalian cell. The
vector encodes three-FLAG epitope (DYKDHDGDYKDHDIDYKDDDDK)
at the N-terminus inserted after Met. The plasmid is a shuttle vector
for Escherichia coli with ampicillin resistance and contains a CMV
promoter. This construct was used to introduce the mutations in the
ASCT2 protein. The amino acid replacements were performed with
complementary mutagenic primers (N163Q forward CTCCGCCGCCAT
CCAAGCCTCCGTG, N163Q reverse CACGGAGGCTTGGATGGCGGCGGAG,
N212Q forward TATGAAGAGAGGCAAATCACCGGAACC, N212Q reverse
GGTTCCGGTGATTTGCCTCTCTTCATA) using the overlap extension
method and the High-Fidelity PCR System [32,33]. The PCR products
were puriﬁed by the QIAEX II Gel Extraction Kit (QIAGEN), digested
with HindIII and KpnI (restriction sites added at the 5′ end of forward
and reverse primers, respectively) and ligated into the same mammali-
an expression vector. All mutations were veriﬁed by DNA sequencing.
2.3. Cell culture
HEK293 cells were maintained in Dulbecco's Modiﬁed Eagle
Medium (DMEM) supplemented with 10% (v/v) fetal bovine serum
(FBS), 1 mM glutamine and 1 mM sodium pyruvate. Cells were grown
on 10 cm2 plates at 37 °C in a humidiﬁed incubator and a 5% CO2
atmosphere.
2.4. SDS-polyacrylamide gel electrophoresis and western blotting
The human cells or rat kidney cortex (where ASCT2 is expressed [9])
homogenate was solubilized in RIPA buffer (20 mM Tris–HCl pH 7.5,
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% NP-40, 1% sodium
deoxycholate) supplemented with protease inhibitors. The proteins
were separated on a 12% polyacrylamide gel and transferred to nitrocel-
lulose membrane. The nitrocellulose membrane was treated with
blocking buffer for 1 h at room temperature. The membrane was then
incubated in a solution of the primary antibody, a rabbit anti-FLAG or
a rabbit anti-ASCT2 and diluted 1:5000 or 1:2000 with the blocking
buffer overnight at 4 °C, respectively. The blot was washed three times
at room temperature. It was then incubated with the secondary
antibody, anti-rabbit IgG, a peroxidase-linked species-speciﬁc whole
antibody diluted 1:10,000 with the blocking buffer for 1 h at room
temperature and revealed by chemiluminescence.
2.5. Transport measurements in cells
HEK 293 cells were seeded onto 12 well plates and cultured using
standard culturing conditions until they reached 80% conﬂuence.
Cells were transfected with Lipofectamine transfection reagent accord-
ing to the manufacturer's procedures: 0.5 μg of p3XFLAG-CMV-7.1-
ASCT2 WT, p3XFLAG-CMV-7.1-N161Q, p3XFLAG-CMV-7.1-N212Q and
p3XFLAG-CMV-7.1-N163/212Q diluted in 50 μL Opti-MEM were com-
bined with 1.5 μl of Lipofectamine in 50 μL Opti-MEM. After 20 min
incubation at room temperature the mixture was added to cell culture
for 5 h at 37 °C in a CO2 incubator. After incubation the medium was
replaced with DMEM supplemented with 10% (v/v) FBS, 1 mM Gln
and 1 mM sodium pyruvate; 24 h after transfection, cells were used
for transport assay of L-[3H]glutamine. Cells were rinsed twice with
warm transport buffer: 20 mM THCl pH 7.4, 3 mM K2HPO4, 1 mM
CaCl2, 5 mM glucose, 130 mM NaCl, 10 mM BCH, and 10 mM MeAIB.
Radiolabeled 10 μM [3H]glutamine was added and the transport
reactionwas terminated at the indicated times by discarding the uptake
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buffer (0.5 ml per well per rinse) plus 10 μMMersalyl. Cells from each
well were solubilized in 500 μl of 1% TX-100 solution. Cell extracts
were counted for radioactivity (400 μl). The remaining 100 μl in each
well were used for protein concentration assay. Na+-dependent gluta-
mine transport was evaluated by subtracting the transport values of
each ASCT2 mutant from those deriving from cells transfected with
empty vector.2.6. Transport measurements in proteoliposomes
HEK 293 cells were transiently transfected as above described then
lysed with RIPA Buffer. Total lysate (20 μg) was reconstituted in proteo-
liposomes using a batch wise procedure [34]. The mixed micelles con-
taining detergent, protein and phospholipids were incubated with
0.5 g Amberlite XAD-4 resin under rotatory stirring (1200 rev/min) at
room temperature (25 °C) for 40min [35]. The composition of the initial
mixture used for reconstitution was: 20 μg protein, 120 μL of 10% (v/v)
C12E8, 100 μL (v/v) of 10% egg yolk phospholipids (w/v) in the form of
sonicated liposomes, 10 mM L-glutamine and 20 mM Tris/HCl pH 7.0
in a ﬁnal volume of 700 μL [25]. Transport was started by adding
50 μM [3H]glutamine to 100 μL of proteoliposomes previously subjected
to Sephadex G75 chromatography to remove external substrate. Trans-
port was stopped at the indicated times according to stop inhibitor
method and radioactivity was counted as previously described [25]. To
calculate kinetic parameters, transport rates were measured at 10 min
transport (i.e., within the initial linear range of the time course in
proteoliposomes) as dependence on [3H]glutamine concentration rang-
ing from 10 μM to 300 μM. Experimental data were ﬁtted in Michaelis–
Menten equation using non-linear ﬁtting analysis by Graﬁt software
(version 5.0.13).2.7. In vitro endoglycosidase treatment
Cells expressing WT and mutant ASCT2 were solubilized as above.
N-glycosidase Fwas added to 20 μg of total lysate for 1 h at 37 °C follow-
ing manufacturer's procedures. The reaction was then terminated by
storage at −80 °C. Frozen aliquots were thawed and subjected to
SDS-PAGE followed by immunoblotting analysis.2.8. Confocal microscopy
HEK 293 cells were seeded onto cover slip and cultured using
standard culturing conditions until 50–70% conﬂuence. Cells were
transfected with PolyJet transfection reagent according to the
manufacturer's procedures: 0.5 μg of p3XFLAG-CMV-7.1-ASCT2 WT,
p3XFLAG-CMV-7.1-N161Q, p3XFLAG-CMV-7.1-N212Q and p3XFLAG-
CMV-7.1-N163/212Q diluted in 25 μl of serum-free DMEM was com-
binedwith 1.5 μl of PolyJet diluted in the samemedium. After 15min in-
cubation at room temperature the mixture was added to the cell
culture; 24 h after transfection cells were ﬁxed with 4% (w/v) parafor-
maldehyde (15 min; 37 °C). After rinsing with PBS, cells were blocked
with 10% (v/v) bovine serum albumin in PBS for 45 min at room tem-
perature. Cells were then incubated with the rabbit monoclonal anti-
FLAG antibody at 1:500 dilution for 1 h followed by Alexa Fluor 594-
conjugated anti-rabbit secondary antibody at 1:300 dilution for
45 min. The cover slips were then washed three times in PBS and
mounted with DAKOmountingmedium. Confocal microscopy was per-
formed using a Leica confocal microscope (40× oil immersion lens). To
evaluate ER to Golgi trafﬁcking, transfected cells were incubated with
5 μM Brefeldin-A for 7 h to inhibit ER to Golgi protein trafﬁcking and
then rinsed twicewith 1× PBS towashout BFA. After that, cells were in-
cubated in FBS free DMEM containing cycloheximide (1 mM) for in-
creasing time points.2.9. Assessment of ASCT2 endocytosis by reversible biotinylation
HEK293 cells seeded on poly-D-lysine-coated 6-well plates and
cultured using standard culturing conditions up to 70–80% conﬂuence.
Cells were transfected with PolyJet transfection reagent according
to the manufacturer's procedures with 1 μg of p3XFLAG-CMV-7.1-
ASCT2 WT, p3XFLAG-CMV-7.1-N161Q, p3XFLAG-CMV-7.1-N212Q and
p3XFLAG-CMV-7.1-N163/212Q. On the day of the endocytosis assay,
the cells were washed twice in ice-cold PBS (pH 8.0) and incubated
with 0.75 ml of disulﬁde-cleavable biotin (sulfo-NHS-SS-biotin) diluted
in PBS (pH 8.0) for 45min at 4 °C. Sulfo-NHS-SS-biotin does not perme-
ate plasma membrane, thus, only cell surface proteins are covalently
labeled on extracellular Lys. Then, cells were incubated for 30 min in
PBS containing 100 mM glycine to quench all non-reacting biotin. Cells
were incubated again in pre-warmed DMEM containing 10% (v/v) FBS
at 37 °C and 5% CO2 for increasing times (0–60 min) to allow the
endocytosis of labeled surface protein. At the end of each time point,
cells were immediately rinsed with PBS and incubated with the cell-
impermeant reducing agent 100 mM 2-mercaptoethanesulfonic acid
(MESNA) solubilized in PBS, pH 8.0 at 4 °C for 40 min and washed
twice in ice-cold PBS containing 120 mM iodoacetamide. MESNA was
used to cleave the NHS-SS-biotin disulﬁde bond and to strip off any re-
sidual surface biotin. The endocytated biotinylated proteins protected
from the stripping were the only biotinylated protein. Cells were then
solubilized in RIPA buffer, and biotinylated ASCT2 was isolated using
monomeric streptoavidin beads. Using this procedure the endocytated
ASCT2-NHS-SS-biotin which was protected from reduction, could be
subsequently isolated by streptavidin afﬁnity chromatography and
detected by immunoblotting. To determine the endocytic rate, the
amount of internalized ASCT2was compared to the total surface control
labeled at time zero. The MESNA stripping efﬁciency was greater than
95% based on reduction of the disulphides ASCT2-NHS-SS-biotin. After
immunoblotting, the intensity of the band derived from cells immedi-
ately exposed to MESNA was subtracted as background from all other
band intensities [27].
2.10. Evaluation of protein stability
HEK293 cells were seeded on 6-well plates and cultured using
standard culturing conditions up to 70–80% conﬂuence. Cells were
transfected with PolyJet transfection reagent according to the manu-
facturer's procedures with 1 μg of p3XFLAG-CMV-7.1-ASCT2 WT,
p3XFLAG-CMV-7.1-N163Q, p3XFLAG-CMV-7.1-N212Q and p3XFLAG-
CMV-7.1-N163/212Q. Cells were incubated over increasing times with
cycloheximide (20 μg/ml) to inhibit further protein synthesis. At each
time point cells were harvested, lysed, and subjected to SDS-PAGE
followed by immunoblot analysis [36,37].
2.11. Other methods
The homology structural model of hASCT2 was built using the
crystal structure (1XFH) of the glutamate transporter homologue from
P. horikoshii as a template. The optimized alignment was used to run
the program Modeller 9.11. The N-glycosylation sites were predicted
by NetNGlyc 1.0 Server. The amount of protein in total lysate was
calculated with Lowry-Folin assay. The quantiﬁcation of protein bands
detected by immunoblotting was estimated by using the Chemidoc
imaging system equipped with Quantity One software (Bio-Rad) as
previously described [38].
3. Results
3.1. Bioinformatic and structural analysis
Bioinformatic analysis using NetNGlyc 1.0 revealed that ASCT2
contains two putative N-glycosylation sites, corresponding to residues
Fig. 1. Homology model of hASCT2. Overall structure of trimeric hASCT2 viewed parallel to membrane. Monomers are distinguished by different gray scales. The two N-glycosylated
residues (N163 and N212) are represented in a space-ﬁlled view and highlighted. The membrane is indicated by black lines.
1639L. Console et al. / Biochimica et Biophysica Acta 1853 (2015) 1636–1645N163 and N212 which are located in the large extracellular loop be-
tween the third and fourth transmembrane segment. It was previously
demonstrated that functional ASCT2 has an oligomeric structure
consisting of two or three subunits similar to the glutamate transporter
of P. horikoshii [23]. In this oligomeric form, all six putative glycosylated
Asn residues protrude towards the extracellular environment (Fig. 1).
This arrangement agreeswith the ﬁnding that the protein is structurally
and functionally asymmetric and all the subunits show the same orien-
tation in the reconstituted system as in the native membrane [8,25].
3.2. Identiﬁcation of N-linked glycosylation sites
We hypothesized that the glycosyl moieties linked to the Asn
residues might be involved in cell-surface expression of the transporter.
To conﬁrm that these residues were indeed glycosylated, we performed
single or double substitution of the two Asn residues (N163 and N212)
of the consensus sequence for N-glycosylation (N-X-S/T), with gluta-
mine by site-directed mutagenesis and tested for loss of glycosylation.
HEK293 cells were transiently transfected with a plasmid encoding
the full-length WT or mutant ASCT2 tagged at the N-terminus with
FLAG. The effect of removal of the putative N-glycosylation sites and
treatment with N-glycanase on the molecular weight of ASCT2 were
ﬁrst evaluated. In the absence of glycosidase treatment, immunoblot-
tingwith anti-FLAG antibody highlighted that HEK293 cells, transfected
withWT ASCT2, displayed several bands with apparentmolecular mass
varying from about 80 kDa to 50 kDa (Fig. 2). Cells transfected with the
single mutant N163Q or N212Q displayed bands from about 70 kDa toFig. 2. Effect of N-glycosidase F on ASCT2. (A)Whole extracts of HEK293 cells transiently transfe
electrophoresis (20 μg protein/lane), blotted, and probedwith anti-FLAG antibody as described
F (500 u) for 1 h at 37 °C. (B) Whole extract of rat kidney brush border vesicles were separated
with anti-ASCT2 antibody as described in Materials and Methods. Lanes marked with plus wer50 kDa, respectively. The double mutant N163/212Q displayed a single
band of about 50 kDa, conﬁrming that indeed the two glycosylation
sites carry glycosyl moieties which are completely absent in the double
mutant. After treatment of WT and single mutants with N-glycanase,
the protein patterns were converted to that of the double mutant,
i.e., a single protein band of about 50 kDa was present (Fig. 2A). Note
that the apparent molecular mass of N-glycanase treated protein
corresponded to that of the ASCT2 over-expressed in P. pastoris,
i.e., without glycosyl moieties [8]. These data conﬁrm that the WT pro-
tein contains glycosyl moieties linked to the N-glycosylation sites at
residues N163 and N212. The same experiment was performed on
protein extracted from rat kidney; also in this case, ASCT2 shows glyco-
sylation moieties, similar to those of protein over-expressed in HEK293
cells, which disappeared upon N-glycanase treatment (Fig. 2B).
3.3. Membrane biotinylation and transport assay
Weanticipated that N-glycosylationwould inﬂuence the presence of
ASCT2 at the plasma membrane. To conﬁrm this, the relative presence
of ASCT2 (WT andmutants) was evaluated using a protein biotinylation
assay involving membrane-impermeant sulfo-NHS-biotin. Biotinylated
proteins were collected with streptavidin resin, subjected to SDS-
PAGE followed by immunoblotting with anti-FLAG antibody. Interest-
ingly, the presence at the surface of the doublemutant was signiﬁcantly
reduced in comparison to WT, while the single mutants showed a
comparable or slightly lower level to WT (Fig. 3A). This difference is
not due to decreased overall protein being produced because totalcted with ASCT2WT ormutant constructs were separated by 12% SDS-polyacrylamide gel
inMaterials andMethods. Lanesmarkedwith pluswere treated in vitrowithN-glycosidase
by 12% SDS-polyacrylamide gel electrophoresis (80 μg protein/lane), blotted, and probed
e treated in vitro with N-glycosidase F (500 u) for 1 h at 37 °C.
Fig. 3. Role of glycosylation on presence of ASCT2 at the plasmamembrane and on functionality. A) Cell surfacebiotinylation of ASCT2 inHEK293 cells. Surface protein fractions obtained by
incubation of total lysateswith avidin beads,was entirely loaded on SDS-PAGE forwestern blot analysis (ASCT2membrane fraction); ASCT2 total lysate is shown as control; actin is shown
as an additional control of total lysate loading. ASCT2 or actin was immunodetected by anti-FLAG or anti-actin, respectively. Representative blots are shown. The histogram represents
scanning densitometry of 3 immunoblots with similar results for quantiﬁcation; light gray columns represent the percentage of band intensity compared to WT of total protein extract;
dark gray columns represent the percentage of band intensity compared to WT of surface protein fractions. Signiﬁcantly different fromWT as estimated by Student's t-test (**P b 0.01).
B) Intact HEK293 cells transiently transfectedwith empty vector (Δ dashed line),WT (○), N163Q (●), N212Q (□) or N163/212Q (■) constructs were tested for uptake of [3H] glutamine.
Transport reaction was terminated at the indicated times as described in Materials and methods. C) Lysate from HEK293 cells transiently transfected with empty vector (Δ dashed line),
WT (○) N163Q (●) N212Q (□) or N163/212Q (■) constructs were reconstituted in proteoliposomes and tested for uptake of [3H]glutamine. The transport reaction was stopped at the
indicated times as described in Materials and methods. Results are means ± S.D. from three independent experiments.
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(Fig. 3A).
ASCT2 transport of [3H] glutamine was measured in cells following
transient transfection with the WT or glycosylation-deﬁcient mutants
(N163Q, N212Q and N163/212Q) in comparison to empty vector. The
singlemutant, N212Q, and doublemutant, N163/212Q, exhibited trans-
port activities of about half and one fourth, respectively, of WT levels
(Fig. 3B) which correlates with a lower expression of these mutants at
cell-surface (Fig. 3A, membrane fraction). In contrast, the single mutant
N163Q, exhibited a transport activity that was comparable to WT. To
determine if mutations affect intrinsic transport activity, equal amounts
of protein extracted fromHEK293 cells, transfected withWT, mutant or
empty vector constructs, were reconstituted in liposomes. Transport
activity was measured as uptake of [3H] glutamine in exchange with
unlabeled glutamine in all the samples in comparison to extract from
cell transfected with empty vector (Fig. 3C). The feature of this tech-
nique allowed us to abolish the differences in transport activity deriving
from different expression in plasma membrane among the four con-
structs. These analyses highlighted that all mutants possess transport
activity comparable to WT indicating that absence of glycosylation
does not affect the intrinsic activity of ASCT2 but only the amount of
protein reaching cell surface (Fig. 3C). In the same proteoliposomes
model, Km values for WT, N163Q, N212Q and N163/212Q were mea-
sured as described in Materials and methods being 31.4 ± 4.7 μM,
35.6±8.3 μM, 29.3±5.4 μMand38.3±6.3 μM, respectively. Kmvalues
for mutants are not signiﬁcantly different fromWT as determined from
ANOVA one way test for p b 0.05.3.4. Endocytosis of surface ASCT2
Changes in the rate of endocytosis could be responsible for altering
the surface expression and function of ASCT2. Using a reversiblebiotinylation strategy, the endocytosis of ASCT2was examined by quan-
tifying the fraction of surface protein that moves in a time-dependent
manner (from 15 to 60 min) into the cytosol. Data show that single
(N212Q) and double (N163-212Q) glycosylation mutants have in-
creased rates of endocytosis compared to WT (Fig. 4). WT protein can
be visualized (by immunoblotting) intracellularly at 60 min (Fig. 4A),
while single (N212Q) and double (N1630212Q) are internalized much
sooner (by 30 min). The percentage of ASCT2 internalization was en-
hanced inN-linked glycosylation doublemutants over the same time in-
terval (Fig. 4B). Interestingly, N163Q showed an internalization pattern
similar toWT, while themutant N212Q behaved similarly to the double
mutant. The initial rate of ASCT2 internalizationwas estimated by ﬁtting
the fraction of internalized ASCT2 as a function of time (Fig. 4A and B).
As shown in Table 1, the single mutant N212Q and the double N163/
212Q showed signiﬁcantly enhanced internalization rate respect to
the WT. These data conﬁrm the earlier ﬁndings (Fig. 3) which suggest
that the glycosylation deﬁcient mutants N212Q and N163-212Q are
present at the membrane at lower levels than WT.3.5. Analysis of stability of ASCT2
To determine the importance of N-glycosylation on ASCT2 stability,
HEK293 cells were transiently transfected with ASCT2 WT or mutants
and incubatedwith cycloheximide (20 μg/ml) to inhibit protein synthe-
sis (Fig. 5). After incubation for 2, 4 and 10 h, cells were harvested, lysed,
and subjected to SDS-PAGE and immunoblot analysis (Fig. 5). Band
density was quantiﬁed and normalized so that the density at time 0
was 100%. Data show (Fig. 5A and C) that WT and N212Q are approxi-
mately equivalently stable up to 10 h.MutantN163Q possessed stability
slightly lower than WT (Fig. 5B). However, in contrast, the N163/212Q
double mutant showed a clear decrease in stability after 10 h incuba-
tion (Fig. 5D). To conﬁrm these data, same cells were analyzed by
Fig. 4. Time course for endocytosis of surface hASCT2. HEK293 cells expressing ASCT2 WT or mutant constructs were surface-biotinylated with cleavable biotin, incubated for different
times at 37°C and strippedwith cell-impermeantMESNA. Biotinylated proteins were isolated using avidin and quantiﬁed by immunoblot analysis as described inMaterials andmethods.
A) Representative immunoblots for total surface (S) and for the internalized hASCT2 at different times (15, 30 and 60min) are shown. Stripping efﬁciency conﬁrmed approximately 95%
removal of NHS-SS-biotin from cell surface protein. T indicates the ASCT2 total lysate shown as control; A indicated actin, shown as loading control for ASCT2 total lysate; M indicates the
ASCT2 membrane fraction obtained as described in legend of Fig. 3 and Materials and methods. ASCT2 or actin has been immunodetected by anti-FLAG or anti-actin, respectively.
B) Quantiﬁcation of internalized hASCT2. Data are derived from the band intensity at the different time points (15, 30, 60 min) as % comparison of the total surface protein (S). Dark
gray represents WT, gray represents N163Q, light gray represents N212Q and white represents N163/212Q. Results are means ± S.D. from three independent experiments. Statistical
analysis was performed for each mutant respect to the corresponding WT by Student's t-test, at the different times. Signiﬁcantly different (*P b 0.05; **P b 0.01).
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times. Confocal analysis conﬁrmed the previous data that such cells
transfected with single mutants N163Q and N212Q displayed a lossTable 1
Effect of N-linked glycosylation on the initial rate of endocytosis and the half-life time of
ASCT2 in HEK-293 cells. Data were obtained as described in Figs. 4 and 5. The initial rate
of internalization was calculated by ﬁtting the fraction of internalized ASCT2 as a function
of time. The Log of the percentage of density (Fig. 5) was plotted versus time and half-life
was calculated from the Log of 50%.
WT N163Q N212Q N163-212Q
Initial rate of internalization 0.4 0.5 1.2 1.2
Half-life time (h) 79 40 29 12of signal from the plasma membrane similar to that of WT at 7 h
(Fig. 5E) while the double mutant showed strikingly less signal at the
plasma membrane for all time points. By 7 h, ﬂuorescent signal had
nearly disappeared, indicating that the double mutant was less stable
than either WT or single mutants and conﬁrming western blot analysis
(Fig. 5A–D). These results established that WT and single mutants were
more stable in the membrane with respect to the N163/212Q double
mutant.
3.6. Trafﬁcking of ASCT2 from the ER to the plasma membrane
The different levels of transporter at the cell-surfacemay result from
variations of endocytosis, degradation and/or altered trafﬁcking fromER
to plasma membrane as a consequence of the lack of N-glycosylation
Fig. 5. Stability ofASCT2varieswith glycosylation level. HEK293 cellswere transiently transfectedwithASCT2WT(A)orN163Q (B),N212Q(C),N163/212Q (D). After 24h, cellswere cultured in
the presence of cycloheximide (20 μg/ml) and lysed at 0, 2, 4, and 10 h. Cell lysateswere separated by SDS-PAGE and subjected to immunoblot analysis using anti FLAG-antibody as described in
Materials andmethods. Anti actin is used as loading control. The band intensity,measured andnormalized so that the density at time 0was 100%,was plotted. Signiﬁcantly different fromWTas
estimated by Student's t-test (*P b 0.05; **P b 0.01). Representative immunoblots are shown. Results are means ± S.D. from three independent experiments. (E) The same samples from A–D
were subjected to confocal analysis. Cells were transiently transfectedwith ASCT2WTormutant constructs. After 24 h, cellswere cultured in the presence of cycloheximide (20 ug/ml), ﬁxed at
0, 2, 4, 7 h and analyzed by confocal microscopy as described in Materials and methods. Confocal images show a single, representative, section of a Z-series taken through the entire cell.
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themembrane,we repeated previous assays in the presence of brefeldin
(BFA), an inhibitor of trafﬁcking between the ER and plasmamembrane[39]. Treatment with BFA led to retention of tagged-ASCT2 (whether
mutant or WT) inside the cell i.e. in the ER (Fig. 6). Removal of BFA
was followed by monitoring of ASCT2 trafﬁcking over the course of
Fig. 6. Trafﬁcking of ASCT2 from the ER to the plasma membrane varies with level of glycosylation. HEK293 cells transiently transfected with ASCT2 WT or N163/212Q constructs were
treatedwith BFA (5 μM, 7 h). hASCT2was retained in the ER and then rescued by BFA washout. Cells were ﬁxed and labeled at the indicated times as described inMaterials and methods.
Confocal images show a single, representative, section of a Z-series taken through the entire cell.
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could be seen in the plasma membrane after the ﬁrst hour. On the con-
trary, doublemutantwas located in the cytosol and only after two hours
some signal was associated with the plasma membrane. This delay in
reaching plasma membrane supports our hypothesis that absence of
glycosylation at N163 and N212 results in a delayed trafﬁcking of
newly synthesized protein to the plasma membrane.
4. Discussion
One of the major, but still unsolved, fundamental biology issues
concerning ASCT2 has been clariﬁed in the study presented here.
Using different experimental approaches, we have conﬁrmed that
transiently transfected ASCT2 is trafﬁcked to plasma membrane within
1 h and then is internalized to be degraded. We show here that the
overall process requires the presence of N-glycosyl moieties on residues
N163 and N212. The homology structure of ASCT2 built on the basis
of the bacterial Gltph structure [23], highlights that the two predicted
N-glycosylation sites and hence, the associated glycosyl moieties are
exposed towards the external environment, as expected. Functional
data, derived from previous studies, show that the orientation of
ASCT2 is as depicted in Fig. 1, both in native and in artiﬁcial membranes
[8,25]. We demonstrated the involvement of the glycosyl moieties
in delivery of ASCT2 to plasma membrane and demonstrated that
at least one of the glycosyl moieties of ASCT2 is required for effective
protein targeting to the plasma membrane. Abrogation of bothglycosylation sites led to the most striking effects but interestingly gly-
cosylation on theN212 site appears to bemore critical to presence of the
protein at the plasma membrane than that on N163, since the surface
expression of the N212Q mutant is more similar to the double mutant
than N163. Importantly, functional assays of the glycosylation-
deﬁcient ASCT2 constructs in native cell membranes and in proteolipo-
somes, demonstrated that presence or absence of N-glycosylation moi-
eties has no inﬂuence on the intrinsic function of the transporter.
Indeed, all three mutants are fully functional when assayed in proteoli-
posomes. This experimental strategy allows measurement of transport
activity of solubilized total expressed protein, even if not targeted to
the plasmamembrane. In contrast, transport assays in intact cells detect
only the plasma membrane targeted protein. Kinetic analyses revealed
very similar Km for WT and mutants indicating that all the proteins
are properly folded. These ﬁndings are in line with previous data on
the endogenous protein, extracted in native form from HeLa cells and
reconstituted in proteoliposomes before and after glycosidase treat-
ment [25] conﬁrming that glycosylation does not play a role in function-
ality once the transporter is in place. Similar roles of glycosylation were
described for other transporters [40] such as the intestinal anion ex-
changer (SLC26A3) and the carnitine transporter (OCTN2, SLC22A5). In-
deed, the functional properties of the deglycosylated anion exchanger
were not appreciablymodiﬁed,while itsmembrane expressionwas sig-
niﬁcantly decreased [29]. In the case of OCTN2, it was suggested that
glycosylation has a role in trafﬁcking even though it could not be ex-
cluded a minor role in substrate binding [41]. In other cases, such as
1644 L. Console et al. / Biochimica et Biophysica Acta 1853 (2015) 1636–1645the GLUT1 or the dopamine transporter (DAT), N-glycosylation plays
roles both in trafﬁcking and in transport function [27,42,43].
In the case of ASCT2, the presence of several species with different
apparent molecular mass in the total cell lysate (Fig. 2) compared to a
single protein band in the plasma membrane fraction (Figs. 3 and 4)
suggests that the plasma membrane-associated isoform is homo-
geneously glycosylated. The other observed species represents, thus,
different stages of glycosylation or progressive degradation of the
internalized protein. These data correspond with previous ﬁndings
for other proteins which suggest that N-glycosylation is associated
with protein stability [30] and that absence of glycosylmoieties result-
ed in a faster degradation. Indeed, confocal images (Fig. 5E) showed
intracellular ﬂuorescence associated with the double mutant in line
with the faster rate of degradation (see Fig. 5). Taken together, these
results suggest that N-glycosylation favors delivery to the membrane
and slows down protein endocytosis and, hence, increases duration
at the membrane and/or resistance to degradation. This supposition
is both quantitatively and qualitatively demonstrated by western blot
and confocal images, respectively (Fig. 5). Indeed, upon cyclohexymide
treatment the total amount of N163Q and particularly N163/212Q
decreased faster than wild type, i.e., mutants are internalized before
WT; imaging conﬁrms that at longer times WT remains associated
with the plasma membrane, while glycosylation defective proteins
are mainly in the cytosol (Fig. 5E). The glycosyl moiety linked to
N163 has probably a major role in protein stability, as indicated by
the similar behavior of the N163Q and N163/212Q mutants (Fig. 5B
and D). The double mutant shows the highest impairment of both
targeting and residence inmembrane. The presence of spotted ﬂuores-
cence especially visible in the double mutant transfected cells (see
Fig. 5E) indicates that glycosylation inﬂuences also the intrinsic stabil-
ity of the protein.
The results of this study may have implications in pathology, since
ASCT2 is over-expressed in several human cancers [1,20]. Therefore,
studying the role of glycosylation in trafﬁcking is also important since
cancer cells exhibit altered patterns of protein glycosylation. Aberrant
glycosylation of cell-surface proteins has been linked to cancer-cell
adhesion, invasion, and metastasis [30,44]. The glucose transporter
GLUT1 experienced structural changes in the N-linked sugar chains in
a human cervical carcinoma increasing the availability of glucose for
transformed cells [45].
In conclusion, an essential role of N-glycosylation in trafﬁcking and
membrane stabilization of ASCT2 has been revealed in this study. Glyco-
sylation does not correlate with functionality, since non-glycosylated
ASCT2 protein, either mutated or over-expressed in yeast, is correctly
inserted into artiﬁcial membranes and reaches the quaternary structure
necessary to accomplish its intrinsic transport activity (see Fig. 2
and [36]). These results highlight the physiological importance of
N-glycosylation as a part of the regulatory context that allows ASCT2
to function with a wide distribution of tissues and in overall amino
acid homeostasis.
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